DHR · Danaher Corporation
$191.50
+1.30% last session
End-of-day data · updated 2026-07-28
Market cap
$138B
Enterprise value
$162B
Trailing P/E
35.0
Forward P/E
21.2
Dividend yield
1.0%
Beta
0.82
Avg volume
5M
Employees
58K
2D change
—
5D change
2.08%
10D change
-3.60%
30D change
0.16%
60D change
7.79%
MTD change
1.44%
YTD change
-13.80%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DHR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-22
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$195
+1.8% vs priceRBC Capital
Outperform$215
+12.3% vs priceHSBC
Buy$230
+20.1% vs priceCitigroup
Neutral$95.00
-50.4% vs priceMorgan Stanley
Overweight$255
+33.2% vs priceUBS
Buy$250
+30.5% vs priceBarclays
Overweight$230
+20.1% vs priceGoldman Sachs
Buy$230
+20.1% vs priceJP Morgan
Overweight$275
+43.6% vs priceJefferies
Buy$265
+38.4% vs priceBank of America
Buy$220
+14.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-22 | Wells Fargo | Maintains | Equal-Weight | $212 → $195 |
| 2026-07-22 | TD Cowen | Maintains | Buy | $240 → $236 |
| 2026-07-22 | Stifel | Maintains | Buy | $260 → $220 |
| 2026-07-22 | Guggenheim | Maintains | Buy | $235 → $200 |
| 2026-07-22 | RBC Capital | Maintains | Outperform | $200 → $215 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $232 → $230 |
| 2026-06-11 | Piper Sandler | Initiates | Neutral | $0.00 → $200 |
| 2026-06-03 | HSBC | Maintains | Buy | $270 → $230 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.6% above the 50-day MA ($185.03).
- Price vs 200-day MA: Trading 2.0% below the 200-day MA ($203.16).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.86) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($161.57) and high ($241.04).
DHR Price Chart
Loading chart for DHR…
Fundamentals
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$208B -3.3% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -17.8% YTD
A
Agilent Technologies, Inc.
$39B 1.9% YTD
NTRA
Natera, Inc.
$37B 12.6% YTD
IQV
IQVIA Holdings, Inc.
$36B -5.4% YTD
WAT
Waters Corporation
$36B -2.3% YTD
ILMN
Illumina, Inc.
$29B 44.5% YTD
MTD
Mettler-Toledo International, I
$27B -4.2% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.